GLP-1 drugs are the biggest thing to happen to the weight loss market in generations, with Eli Lilly's GLP-1 drugs bringing in just under $15bn in the second quarter alone, and PwC predicting one in eight UK adults could be on them by 2027. More people on the drugs means more people eating less, with trials showing calorie intake cut by up to 39% and 88% of users falling short of recommended protein intake. That gap has created a second category alongside the drugs, and the supplement industry, already set up to serve exactly this need, has moved into it fast.
A 2025 review published in the journal Nutrients found users developing vitamin and mineral deficiencies within a year of starting a GLP-1 drug, most commonly vitamin D.
Holland & Barrett now has a GLP-1 support range, and Walmart and CVS are stocking similar lines in the US. With the shelf built, three brands have shown three different ways to earn a place on it.
Nestlé repackaged brands it already owned into a GLP-1 platform without formulating anything new. When it did launch a dedicated product, the Vital Pursuit range of high-protein frozen meals, its marketing head Jennifer Barnes told FoodNavigator that 77% of sales were coming from people not on the drugs at all, because the positioning suited a far wider group of weight-conscious shoppers than the ones it was built for.
Applied Nutrition won by moving fastest. In July it took Holland & Barrett's first dedicated GLP-1 range exclusively, a nine-product line of protein, hydration, collagen, creatine and digestion products across 400 stores, and the win was being the brand on the shelf while everyone else was still deciding whether to have one.
Thorne has gone a different way. It launched Protein Optimizer on 9 September with GLP-1 users as a named target group, a probiotic and enzyme capsule built on a clinically studied Bacillus coagulans strain rather than another tub of whey, betting that a mechanism will hold a customer's attention longer than a claim on the label.
Clinical research into how much supplement support can actually help someone on a GLP-1 drug is now getting under way, with Erasmus Medical Center running a trial on multivitamins in GLP-1 users and a separate US trial testing protein for muscle preservation. One review put it plainly: until trials like these report, giving supplements to GLP-1 users is a reasonable guess, not a proven fix.
Our read
Being first or being a well-known name has been enough so far, and there's no reason it wouldn't be, as the category's barely a year old. What we'll likely see next is a shift, because these products sit next to a drug that got where it is through years of clinical trials most people will never read but still trust completely.
The people actually recommending this stuff, doctors managing patients on the drug, aren't going to accept "the ingredient's been studied elsewhere" as an answer for much longer. Whoever runs that trial first isn't just adding a claim to a label. They're changing what everyone else on the shelf now has to explain.
Sources: Eli Lilly Q2 results, PwC GLP-1 report, Nutrients review, The Grocer, FoodNavigator, NutraIngredients, Thorne launch, VITAGLP trial


